J9357
J9357 – Injection, valrubicin, intravesical, 200 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 200 MG $1,247.047/unit ASP+6%
📋 J9357 summary
J9357 is a HCPCS Level II J-code used to bill valrubicin, intravesical, 200 mg, billed per 200 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9357: Valrubicin Intravesical Solution, Valstar
Code J9357
Billing unit 200 MG Payment limit $1,247.047/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9357
DescriptorInjection, valrubicin, intravesical, 200 mg
Billing unit200 MG
Payment limit / unit$1,247.047
Est. ASP / unit$1,176.459 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
💊 About Valrubicin Intravesical DRUG GUIDE
Valrubicin Intravesical Solution is used to treat BCG-refractory carcinoma in situ (CIS) of the urinary bladder — meaning bladder cancer that has not responded to BCG immunotherapy.
It is given directly into the bladder (intravesically) rather than taken by mouth or injected into the bloodstream.This treatment is specifically for patients whose cancer has not responded to BCG and for whom having the bladder surgically removed (cystectomy) right away would carry unacceptable health risks.
Clinical overview from our editorial drug guide for Valrubicin Intravesical. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$1,247.047
Est. ASP / unit
$1,176.459 est.
Est. after 2% sequester
$1,222.106
HCPCS dosage
200 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, valrubicin, intravesical, 200 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2009-01-01
Date added2000-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9357 = 200 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9357 WITH EST. MEDICARE PAY
2 NDCs map to J9357. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($1,247.047/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 24201-0101-04 | Valrubicin Intravesical Solution 40 mg/mL SOLUTION, CONCENTRATE | Hikma | 4 VIAL in 1 CARTON (24201-101-04) / 5 mL... | 40 mg/mL | 4 | $4,988.19 | — | ● Active | CMS + PDAC |
| 67979-0001-01 | Valstar valrubicin 40 mg/mL SOLUTION, CONCENTRATE | Endo | 4 VIAL in 1 CARTON (67979-001-01) / 5 mL... | 40 mg/mL | 4 | $4,988.19 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$159K
Claims
28
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$5,679.10
Trend by period
Where J9357 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #538 of 824
#533
DOBUTAMINE HCL-D5W* J1250
$183.5K
#534
TROGARZO J1746
$183.1K
#535
AXOLOTL DUALGRAFT, P... Q4332
$182.5K
#536
FIBRYGA J7177
$178.7K
#537
AMNIOBAND, GUARDIAN... Q4151
$163K
#538
VALRUBICIN* J9357
$159K
#539
DERMABIND FM, PER SQ... Q4313
$158.6K
#540
DACOGEN* J0894
$156.7K
#541
PALONOSETRON HCL J2469
$150.2K
#542
VAXNEUVANCE 90671
$149.4K
#543
DEXRAZOXANE J1190
$142.3K
Total claims — #751 of 824
#746
ZIEXTENZO Q5120
29
#747
HYPERHEP B* 90371
28
#748
SPEVIGO J1747
28
#749
TIGECYCLINE* J3243
28
#750
VFEND IV* J3465
28
#751
VALRUBICIN* J9357
28
#752
PALISADE DM MATRIX P... Q4350
28
#753
RECOMBIVAX HB 90743
27
#754
MORPHINE SULFATE(J22... J2272
27
#755
FIBRYGA J7177
27
#756
REVITA, PER SQ CM** Q4180
27
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $159K | — | 28 | — | $5,679.10 |
| 2025 (Q1-Q4) | $1.32M | 42 | 232 | $31,523.44 | $5,706.83 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$1.03M
Medicare paid
$826.6K
Submitted services
764
Submitted charges
$1.91M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9357 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J9357
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9357 billing FAQ
What is HCPCS code J9357?
J9357 is a HCPCS Level II J-code used to bill Injection, valrubicin, intravesical, 200 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9357?
One unit of J9357 represents 200 MG. Report the number of units equal to the dose administered divided by 200 MG.
How many units of J9357 should I bill?
Divide the dose administered by the code's unit size (200 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9357?
The Medicare Part B payment limit is $1,247.047 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $1,222.106 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9357?
2 NDCs currently map to J9357 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9357 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.